141 related articles for article (PubMed ID: 31070860)
1. Cellular versus acellular matrix devices in the treatment of diabetic foot ulcers: Interim results of a comparative efficacy randomized controlled trial.
Tchanque-Fossuo CN; Dahle SE; Lev-Tov H; West KIM; Li CS; Rocke DM; Isseroff RR
J Tissue Eng Regen Med; 2019 Aug; 13(8):1430-1437. PubMed ID: 31070860
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of tissue engineering products for the management of neuropathic diabetic foot ulcers: an interim analysis.
Frykberg RG; Cazzell SM; Arroyo-Rivera J; Tallis A; Reyzelman AM; Saba F; Warren L; Stouch BC; Gilbert TW
J Wound Care; 2016 Jul; 25(Sup7):S18-S25. PubMed ID: 29027848
[TBL] [Abstract][Full Text] [Related]
3. Cellular versus acellular matrix devices in treatment of diabetic foot ulcers: study protocol for a comparative efficacy randomized controlled trial.
Lev-Tov H; Li CS; Dahle S; Isseroff RR
Trials; 2013 Jan; 14():8. PubMed ID: 23298410
[TBL] [Abstract][Full Text] [Related]
4. A prospective, randomised, controlled, multicentre clinical trial examining healing rates, safety and cost to closure of an acellular reticular allogenic human dermis versus standard of care in the treatment of chronic diabetic foot ulcers.
Zelen CM; Orgill DP; Serena T; Galiano R; Carter MJ; DiDomenico LA; Keller J; Kaufman J; Li WW
Int Wound J; 2017 Apr; 14(2):307-315. PubMed ID: 27073000
[TBL] [Abstract][Full Text] [Related]
5. A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator.
Cazzell S; Vayser D; Pham H; Walters J; Reyzelman A; Samsell B; Dorsch K; Moore M
Wound Repair Regen; 2017 May; 25(3):483-497. PubMed ID: 28544150
[TBL] [Abstract][Full Text] [Related]
6. An aseptically processed, acellular, reticular, allogenic human dermis improves healing in diabetic foot ulcers: A prospective, randomised, controlled, multicentre follow-up trial.
Zelen CM; Orgill DP; Serena TE; Galiano RE; Carter MJ; DiDomenico LA; Keller J; Kaufman JP; Li WW
Int Wound J; 2018 Oct; 15(5):731-739. PubMed ID: 29682897
[TBL] [Abstract][Full Text] [Related]
7. Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers.
Gentzkow GD; Iwasaki SD; Hershon KS; Mengel M; Prendergast JJ; Ricotta JJ; Steed DP; Lipkin S
Diabetes Care; 1996 Apr; 19(4):350-4. PubMed ID: 8729158
[TBL] [Abstract][Full Text] [Related]
8. Human Reticular Acellular Dermal Matrix in the Healing of Chronic Diabetic Foot Ulcerations that Failed Standard Conservative Treatment: A Retrospective Crossover Study.
Zelen CM; Orgill DP; Serena TE; Galiano RD; Carter MJ; DiDomenico LA; Kaufman JP; Keller J; Young NJ; Li WW
Wounds; 2017 Feb; 29(2):39-45. PubMed ID: 28272011
[TBL] [Abstract][Full Text] [Related]
9. Fetal bovine acellular dermal matrix for the closure of diabetic foot ulcers: a prospective randomised controlled trial.
Lantis JC; Snyder R; Reyzelman AM; Van Gils CC; Sigal F; Vayser D; Caporusso JM; Cazzell S; Lavery LA;
J Wound Care; 2021 Jul; 30(Sup7):S18-S27. PubMed ID: 34256588
[TBL] [Abstract][Full Text] [Related]
10. Cellular versus acellular grafts for diabetic foot ulcers: altering the protocol to improve recruitment to a comparative efficacy trial.
Tchanque-Fossuo CN; Dahle SE; Lev-Tov H; Li CS; Isseroff RR
Cutis; 2017 Nov; 100(5):E18-E21. PubMed ID: 29232436
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of acellular dermal matrix in diabetic foot ulcer treatment: A systematic review and meta-analysis.
Guo X; Mu D; Gao F
Int J Surg; 2017 Apr; 40():1-7. PubMed ID: 28232031
[TBL] [Abstract][Full Text] [Related]
12. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers.
Niezgoda JA; Van Gils CC; Frykberg RG; Hodde JP
Adv Skin Wound Care; 2005 Jun; 18(5 Pt 1):258-66. PubMed ID: 15942317
[TBL] [Abstract][Full Text] [Related]
13. Poorly designed research does not help clarify the role of hyperbaric oxygen in the treatment of chronic diabetic foot ulcers.
Mutluoglu M; Uzun G; Bennett M; Germonpré P; Smart D; Mathieu D
Diving Hyperb Med; 2016 Sep; 46(3):133-134. PubMed ID: 27723012
[TBL] [Abstract][Full Text] [Related]
14. A Randomized Controlled Trial Comparing a Human Acellular Dermal Matrix Versus Conventional Care for the Treatment of Venous Leg Ulcers.
Cazzell S
Wounds; 2019 Mar; 31(3):68-74. PubMed ID: 30720443
[TBL] [Abstract][Full Text] [Related]
15. Topical oxygen therapy in the treatment of diabetic foot ulcers: a multicentre, open, randomised controlled clinical trial.
Serena TE; Bullock NM; Cole W; Lantis J; Li L; Moore S; Patel K; Sabo M; Wahab N; Price P
J Wound Care; 2021 May; 30(Sup5):S7-S14. PubMed ID: 33979229
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial.
Marston WA; Hanft J; Norwood P; Pollak R;
Diabetes Care; 2003 Jun; 26(6):1701-5. PubMed ID: 12766097
[TBL] [Abstract][Full Text] [Related]
17. A Prospective, Randomized, Blinded, Controlled Trial Comparing Transdermal Continuous Oxygen Delivery to Moist Wound Therapy for the Treatment of Diabetic Foot Ulcers.
Driver VR; Reyzelman A; Kawalec J; French M
Ostomy Wound Manage; 2017 Apr; 63(4):12-28. PubMed ID: 28448266
[TBL] [Abstract][Full Text] [Related]
18. Wound Conforming Matrix Containing Purified Homogenate of Dermal Collagen Promotes Healing of Diabetic Neuropathic Foot Ulcers: Comparative Analysis Versus Standard of Care.
Chandler LA; Alvarez OM; Blume PA; Kim PJ; Kirsner RS; Lantis JC; Marston WA
Adv Wound Care (New Rochelle); 2020 Feb; 9(2):61-67. PubMed ID: 31903299
[No Abstract] [Full Text] [Related]
19. A Prospective, Randomized, Multicenter, Controlled Evaluation of the Use of Dehydrated Amniotic Membrane Allograft Compared to Standard of Care for the Closure of Chronic Diabetic Foot Ulcer.
Snyder RJ; Shimozaki K; Tallis A; Kerzner M; Reyzelman A; Lintzeris D; Bell D; Rutan RL; Rosenblum B
Wounds; 2016 Mar; 28(3):70-7. PubMed ID: 26978860
[TBL] [Abstract][Full Text] [Related]
20. A purified reconstituted bilayer matrix shows improved outcomes in treatment of non-healing diabetic foot ulcers when compared to the standard of care: Final results and analysis of a prospective, randomized, controlled, multi-centre clinical trial.
Armstrong DG; Orgill DP; Galiano RD; Glat PM; Kaufman JP; Carter MJ; DiDomenico LA; Zelen CM
Int Wound J; 2024 Apr; 21(4):e14882. PubMed ID: 38606794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
